• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·ARCOMA.ST
Share

Arcoma AB Stocks

SEK 8.28Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

SEK 12.30M

SEK 8.28
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Arcoma AB is a global provider that designs, manufactures, and supplies cutting-edge radiology solutions. Their product line features advanced digital x-ray and radiography systems. These versatile systems are suitable for a wide array of radiographic applications and are utilized across various clinical environments, including general practice, musculoskeletal, thoracic, pediatric, and trauma/resuscitation units. The company distributes its products through a network of OEM partners. Arcoma AB was founded in 1990 and is headquartered in Växjö, Sweden.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, undervalued on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of ARCOMA.ST is 9.50 and suggests 13.9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 12:29

Samsung and SK Hynix Plummeted Ahead of Earnings Reports: News from China Fueled Investor Fears

28.07.2026 12:00

Is Cartier the New Birkin? Investors Are Looking for the Next Big Thing in the World of Luxury

28.07.2026 10:42

Top Stories This Morning: New U.S. Rules for AI, a Plunge in Chipmakers’ Stocks and the South Korean Stock Market

28.07.2026 09:00

Rivian is benefiting from the growth of robotaxis. One analyst expects the stock to rise 26%.

28.07.2026 08:00

Germany will cut spending on ammunition. Which company will be negatively affected by this?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026